Neurimmune announced today that it will participate in the AD/PD 2021 Virtual Conference. Roger Nitsch, Neurimmune’s CEO & President, will give a plenary lecture on “Monoclonal Antibodies Targeting Amyloid Beta For the Potential Treatment of Alzheimer’s Disease” on Monday, March 11, at 7:30 a.m. CET.
In addition, Neurimmune’s collaboration partner Biogen (Cambridge, US) will webcast their aducanumab presentations from AD/PD 2021. Please go to the investors section of Biogen’s website to visit the webcasts.
